PP
FULC icon

PDT Partners’s Fulcrum Therapeutics FULC Stock Holding History

PDT Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,280
Closed -$188K – 629
2025
Q2 		$188K Buy
+27,280
New +$146K 0.01% 642
2024
Q2 		– Sell
-49,518
Closed -$467K – 695
2024
Q1 		$467K Buy
+49,518
New +$442K 0.04% 469
2023
Q2 		– Sell
-28,603
Closed -$81.5K – 604
2023
Q1 		$81.5K Sell
28,603
-12,800
-31% -$115K 0.01% 542
2022
Q4 		$301K Buy
+41,403
New +$270K 0.05% 483
2021
Q4 		– Sell
-13,523
Closed -$381K – 922
2021
Q3 		$381K Sell
13,523
-4,477
-25% -$84.8K 0.03% 533
2021
Q2 		$189K Sell
18,000
-2,343
-12% -$23.7K 0.01% 711
2021
Q1 		$240K Sell
20,343
-3,367
-14% -$41.6K 0.02% 663
2020
Q4 		$278K Buy
+23,710
New +$268K 0.02% 560

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PDT Partners's FULC Position: Q3 2025 in Review

PDT Partners sold out of Fulcrum Therapeutics (FULC) in Q3 2025, closing a stake of 27,280 shares — an estimated $188K sold.

PDT Partners first reported a position in FULC in Q4 2020 and held it in 8 quarters. The position peaked at $467K in Q1 2024. 129 funds tracked by Wall St. Rank hold FULC as of Q3 2025.

  • PDT Partners reported no remaining Fulcrum Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PDT Partners sold 27,280 Fulcrum Therapeutics shares in Q3 2025, an estimated $188K.
  • PDT Partners first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 8 quarters.
  • PDT Partners's Fulcrum Therapeutics position peaked at $467K in Q1 2024.
  • 129 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2025.

Based on PDT Partners's 13F filing for Q3 2025, filed 17 Nov 2025.